ArticleBMC gastroenterology2025
Autoimmune liver diseases and systemic rheumatic disorders: exploring their interplay and impact on prognosis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatic control of immunometabolism: implications for the pathogenesis, diagnosis and treatment of rheumatic diseases.Nature reviews. Rheumatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAutoimmune liver diseases (AILDs) are associated with systemic rheumatic diseases (SRDs) and their autoantibodies. This study investigates the prevalence of SRDs and related autoantibodies in AILD patients and their prognostic implications.
methodsWe retrospectively analyzed all AILD patients followed at Emek Medical Center's Hepatology Clinic for SRDs and their autoantibodies. Patients were divided into two groups: AILD with vs. without SRDs and AILD with vs. without autoantibodies. Clinical course, outcomes, and prognostic parameters were compared between these groups.
resultsAmong 157 AILD patients, SRDs were present in 16.8%, and autoantibodies were detected in 40.8%. Patients with both AILD and SRDs exhibited significantly higher frequencies of anti-dsDNA (p = 0.005), anti-RNP (p < 0.001), APLA (p = 0.004), RF (p = 0.02), and anti-Ro (p = 0.001). Notably, AILD patients with autoantibodies had a higher rate of liver transplantation compared to those without (8% vs. 0%, p = 0.036). However, no significant differences in overall prognosis or outcomes were observed between AILD patients with and without SRDs.
conclusionsSRDs and their associated autoantibodies are highly prevalent in AILD patients. The presence of specific autoantibodies, particularly anti-dsDNA, anti-RNP, APLA and anti-Ro may indicate an association with SRDs and could have prognostic value in AILD progression. Further studies are needed to validate these findings and explore their clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.